Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy: A 24-Month Cohort Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Outcomes and Definitions
2.2. Study Population
2.3. Sample Size and Power Analysis
2.4. Anticoagulation and Antiplatelet Therapy
2.5. Statistical Analysis
3. Results
3.1. Bleeding Events
3.2. Thrombotic Events
3.3. Overall Mortality
4. Discussion
Study Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Catella, J.; Bertoletti, L.; Mismetti, P.; Ollier, E.; Samperiz, A.; Soler, S.; Suriñach, J.M.; Mahé, I.; Lorente, M.A.; Braester, A.; et al. Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism. J. Thromb. Haemost. 2020, 18, 1728–1737. [Google Scholar] [CrossRef] [PubMed]
- Escolar, G.; Díaz-Ricart, M.; Cases, A. Uremic platelet dysfunction: Past and present. Curr. Hematol. Rep. 2005, 4, 359–367. [Google Scholar] [PubMed]
- Kozek-Langenecker, S.A.; Masaki, T.; Mohammad, H.; Green, W.; Mohammad, S.F.; Cheung, A.K. Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int. 1999, 56, 299–305. [Google Scholar] [CrossRef]
- Soler-Espejo, E.; Esteve-Pastor, M.A.; Rivera-Caravaca, J.M.; Roldan, V.; Marín, F. Reducing bleeding risk in patients on oral anticoagulation therapy. Expert Rev. Cardiovasc. Ther. 2023, 21, 923–936. [Google Scholar] [CrossRef]
- Königsbrügge, O.; Posch, F.; Antlanger, M.; Kovarik, J.; Klauser-Braun, R.; Kletzmayr, J.; Schmaldienst, S.; Auinger, M.; Zuntner, G.; Lorenz, M.; et al. Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: Cross-sectional results of the Vienna Investigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI). PLoS ONE 2017, 12, e0182798. [Google Scholar]
- Wang, E.Y.; Hulme, O.L.; Khurshid, S.; Weng, L.C.; Choi, S.H.; Walkey, A.J.; Ashburner, J.M.; McManus, D.D.; Singer, D.E.; Atlas, S.J.; et al. Initial precipitants and recurrence of atrial fibrillation. Circ. Arrhythm. Electrophysiol. 2020, 13, e007716. [Google Scholar] [CrossRef]
- Königsbrügge, O.; Meisel, H.; Beyer, A.; Schmaldienst, S.; Klauser-Braun, R.; Lorenz, M.; Auinger, M.; Kletzmayr, J.; Hecking, M.; Winkelmayer, W.C.; et al. Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study. J. Thromb. Haemost. 2021, 19, 2984–2996. [Google Scholar] [CrossRef] [PubMed]
- Van Der Meersch, H.; De Bacquer, D.; De Vriese, A.S. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. Am. Heart J. 2017, 184, 37–46. [Google Scholar] [CrossRef]
- Tan, J.; Liu, S.; Segal, J.B.; Alexander, G.C.; McAdams-DeMarco, M. Warfarin use and stroke, bleeding, and mortality risk in patients with end-stage renal disease and atrial fibrillation: A systematic review and meta-analysis. BMC Nephrol. 2016, 17, 157. [Google Scholar] [CrossRef] [PubMed]
- Elliott, M.J.; Zimmerman, D.; Holden, R.M. Warfarin anticoagulation in hemodialysis patients: A systematic review of bleeding rates. Am. J. Kidney Dis. 2007, 50, 433–440. [Google Scholar] [CrossRef]
- Bansal, N. Use of oral anticoagulation for patients with ESRD on hemodialysis with atrial fibrillation: Verdict 1. Clin. J. Am. Soc. Nephrol. 2016, 11, 2093–2094. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Lei, H.; Yu, L.T.; Wang, W.N.; Zhang, S.G. Warfarin and the risk of death, stroke, and major bleeding in patients with atrial fibrillation receiving hemodialysis: A systematic review and meta-analysis. Front. Pharmacol. 2018, 9, 1218. [Google Scholar] [CrossRef] [PubMed]
- Schulman, S.; Kearon, C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 2005, 3, 692–694. [Google Scholar] [CrossRef]
- Kaatz, S.; Ahmad, D.; Spyropoulos, A.C.; Schulman, S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH. J. Thromb. Haemost. 2015, 13, 2119–2126. [Google Scholar] [CrossRef] [PubMed]
- Wizemann, V.; Tong, L.; Satayathum, S.; Disney, A.; Akiba, T.; Fissell, R.B.; Kerr, P.; Young, E.W.; Robinson, B.M. Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy. Kidney Int. 2014, 66, 65–70. [Google Scholar] [CrossRef] [PubMed]
- Kuno, T.; Takagi, H.; Ando, T.; Sugiyama, T.; Miyashita, S.; Valentin, N.; Shimada, Y.J.; Kodaira, M.; Numasawa, Y.; Briasoulis, A.; et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J. Am. Coll. Cardiol. 2020, 75, 273–285. [Google Scholar] [CrossRef]
- Chan, K.E.; Lazarus, J.M.; Thadhani, R.; Hakim, R.M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J. Am. Soc. Nephrol. 2015, 20, 2223–2233. [Google Scholar] [CrossRef]
- Aursulesei, V.; Costache, I.I. Anticoagulation in chronic kidney disease: From guidelines to clinical practice. Clin. Cardiol. 2019, 42, 774–782. [Google Scholar] [CrossRef]
- Daimon, S. Adverse effect of antithrombotic medications on bleeding events and comparison of antithrombotic agents in hemodialysis patients. Ther. Apher. Dial. 2019, 23, 32–37. [Google Scholar] [CrossRef]
- Olesen, J.B.; Lip, G.Y.; Kamper, A.L.; Hommel, K.; Køber, L.; Lane, D.A.; Lindhardsen, J.; Gislason, G.H.; Torp-Pedersen, C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl. J. Med. 2012, 367, 625–635. [Google Scholar] [CrossRef]
- Liao, J.N.; Chao, T.F.; Liu, C.J.; Wang, K.L.; Chen, S.J.; Lin, Y.J.; Chang, S.L.; Lo, L.W.; Hu, Y.F.; Tuan, T.C.; et al. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int. 2015, 87, 1209–1215. [Google Scholar] [CrossRef]
- Ocak, G.; Noordzij, M.; Rookmaaker, M.B.; Cases, A.; Couchoud, C.; Heaf, J.G.; Jarraya, F.; De Meester, J.; Groothoff, J.W.; Waldum-Grevbo, B.E.; et al. Mortality due to bleeding, myocardial infarction and stroke in dialysis patients. J. Thromb. Haemost. 2018, 16, 1953–1963. [Google Scholar] [CrossRef] [PubMed]
- Shen, J.I.; Montez-Rath, M.E.; Lenihan, C.R.; Turakhia, M.P.; Chang, T.I.; Winkelmayer, W.C. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am. J. Kidney Dis. 2015, 66, 677–688. [Google Scholar] [CrossRef] [PubMed]
- Kai, B.; Bogorad, Y.; Nguyen, L.N.; Yang, S.-J.; Chen, W.; Spencer, H.T.; Shen, A.Y.-J.; Lee, M.-S. Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation. Heart Rhythm 2017, 14, 645–651. [Google Scholar] [CrossRef] [PubMed]
- Heine, G.H.; Brandenburg, V.; Schirmer, S.H. Oral anticoagulation in chronic kidney disease and atrial fibrillation. Dtsch. Arztebl. Int. 2018, 115, 287–294. [Google Scholar] [CrossRef] [PubMed]
- Akbar, M.R.; Febrianora, M.; Iqbal, M. Warfarin usage in patients with atrial fibrillation undergoing hemodialysis in the Indonesian population. Curr. Probl. Cardiol. 2023, 48, 101104. [Google Scholar] [CrossRef]
- Lavalle, C.; Pierucci, N.; Mariani, M.V.; Piro, A.; Borrelli, A.; Grimaldi, M.; Rossillo, A.; Notarstefano, P.; Compagnucci, P.; Dello Russo, A.; et al. Italian Registry in the Setting of Atrial Fibrillation Ablation with Rivaroxaban—IRIS. Minerva Cardiol. Angiol. 2024; ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Cabanas-Grandío, P.; González-Melchor, L.; Caamaño, M.V.; Windcheid, E.F.-O.; Babarro, E.G.; Bobín, O.D.; Portela, M.P.; Delgado, O.P.; Teja, J.E.; Feijoo, M.G.; et al. Health-Related Quality of Life and Satisfaction in Atrial Fibrillation Patients on Anticoagulant Therapy: Differences between Vitamin K Antagonists and Direct Oral Anticoagulants; Results from the Multicentre REGUEIFA Registry. J. Clin. Med. 2024, 13, 5283. [Google Scholar] [CrossRef]
- de Lucena, L.A.; Freitas, M.A.A.; Souza, A.K.C.; Silva, C.H.A.; Watanabe, J.M.F.; Guedes, F.L.; Almeida, J.B.; de Oliveira, R.A. Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Stage 5 Chronic Kidney Disease under Dialysis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Thromb. Thrombolysis 2024, 57, 381–389. [Google Scholar] [CrossRef] [PubMed]
All Patients | Without AF | With AF | ||||
---|---|---|---|---|---|---|
Total | Warfarin + Aspirin | Warfarin | p-Value | |||
Total number of patients | 224 | 181 | 43 (19%) | 19 (44.2%) | 24 (55.8%) | |
Men (%) | 143 (63.8%) | 100 (55.2%) | 30 (69.7%) | 9 (20.9%) | 21 (48.4) | 0.036 |
Age, median (IQR) | 61 (19–89.0) | 58.0 (19–77) | 64.7 (46–89.0) | 70.0 (51.0–89.0) | 68.3 (43.5–76.0) | 0.038 |
Duration of dialysis, months | 66.3 (5–299) | 46.3(5–173) | 60.3 (89–221.0) | 42.6 (25.6–202) | 58.3 (31.7–198.0) | 0.036 |
Comorbidities, n (%) | ||||||
Previous CVI | 20 (8.9%) | 10 (5%) | 10 (23.3%) | 2 (4.6%) | 8 (18.6%) | 0.002 |
Ischemic heart disease | 33 (12.4%) | 19 (10.%) | 14 (32%) | 6 (13.9%) | 8 (18.6%) | 0.71 |
HTA (Hypertension) | 185 (69.3%) | 173 (95.5%) | 12 (27.9%) | 5 (11.6%) | 7 (16.2%) | 0.75 |
Heart failure | 43(19.9%) | 37 (20.4%) | 7 (16.2%) | 4 (9.3%) | 3 (6.9%) | 0.36 |
Diabetes | 68 (30.3%) | 35 (51.4%) | 33 (48.55) | 20 (60.6%) | 13 (39.4%) | 0.022 |
Blood chemistry | ||||||
Hemoglobin g/L | 103.2 + 11.5 | 102.1 ± 11.4 | 103.2 ± 11.1 | 101.3 + 10.1 | 102.1 + 10.2 | 0.9 |
White blood cells count, ×109/L | 6.2 + 2.4 | 6.1 ± 2.1 | 6.3 ± 1.7 | 7.1 + 2.5 | 6.4 + 1.1 | 0.9 |
Platelet count, ×109/L | 164.3 + 68.2 | 197.1 ± 50.2 | 170.5 ± 41.1 | 146.4 + 61.4 | 131.0 + 40.9 | 0.63 |
INR (PT) | 1.6 + 0.4 | 1.3 ± 0.2 | 1.5.0 ± 0.1 | 2.0 + 0.4 | 2.4 + 0.1 | 0.09 |
aPTT (seconds) | 33.6 + 13.7 | 32.2 ± 11.3 | 31.8 ± 13.1 | 33.3 + 4.6 | 38.8 + 9.4 | 0.68 |
Fibrinogen (g/L) | 5.0 + 1.2 | 4.2 ± 1.2 | 5.2 ± 1.4 | 5.6 + 1.4 | 5.4 + 1.2 | 0.88 |
Medications | ||||||
RAAS blockers | 135 (74.5%) | 100 (55.2%) | 35 (81.3%) | 10 (23.3%) | 24 (55.8%) | 0.07 |
Calcium blockers | 106 (58.5%) | 84 (46.4%) | 22 (51.1%) | 10 (23.3%) | 12 (27.9%) | 0.06 |
Statins | 31 (17.1%) | 15 (8.2%) | 16 (37.2%) | 8 (18.6%) | 8 (18.6%) | 0.61 |
Bleeding Outcome | All the Patients (n = 224) | Without AF (n = 181) | With AF (n = 43) | p Value |
---|---|---|---|---|
Any bleeding | 80 (35.7%) | 58 (32.4%) | 22(51.2%) | 0.029 |
• Major bleeding | 21 (9.4%) | 13 (7.18%) | 8 (18.6%) | 0.043 |
• Clinically relevant bleeding | 23 (10.3%) | 20 (11.4%) | 3 (7.0%) | 0.61 |
• Minor bleeding | 24 (10.7%) | 19 (10.5%) | 5 (11.6%) | 1 |
Death due to bleeding | 12 (5.3%) | 6 (3.3%) | 6 (14%) | 0.016 |
Thrombotic Outcome | All the Patients (n = 224) | Without AF (n = 181) | With AF (n = 43) | p Value |
---|---|---|---|---|
Any thrombotic event | 60 (26.8%) | 39 (21.5%) | 21 (48.8%) | 0.0006 |
• Ischemic stroke | 15 (6.7%) | 7 (3.86%) | 8(18.6%) | 0.0117 |
• AVF thrombosis | 28 (12.5%) | 21 (11.6%) | 7(16.2%) | 0.563 |
• Myocardial infarction | 10 (4.5%) | 5 (2.8%) | 5 (11.6%) | 0.034 |
• PTE | 7 (3.5) | 6(3.3) | 1 (2.32) | 1 |
Death due to thrombosis | 12 (5.35%) | 5 (2.8%) | 7 (16.2%) | 0.0016 |
Warfarin | Warfarin + Aspirin | |||
---|---|---|---|---|
HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
Thrombotic event | ||||
• Myocardial infarction | 081 (0.52–0.89) | 0.11 | 0.76 (0.67–1.28) | 0.1 |
• PTE | 0.86 (0.75–1.45) | 0.361 | 0.88 (0.62–1.13) | 0.378 |
• Ischemic stroke | 0.77 (0.41–1.67) | 0.479 | 0.72 (0.05–1.63) | 0.683 |
Bleeding | ||||
• Major bleeding | 1.14 (0.92–3.12) | 0.684 | 2.56 (1.43–4.66) | 0.016 |
• Clinically relevant bleeding | 1.31(1.11–2.81) | 0.254 | 2.34 (1.46–6.13) | 0.0202 |
• Minor bleeding | 0.91 (0.76–1.60) | 0.62 | 1.01 (0.91–1.28) | 0.90 |
All cause deaths | 1.79 (1.45–3.7) | 0.0148 | 1.98 (1.68–5.12) | 0.0163 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dimitrijevic, Z.M.; Mitic, B.P.; Tasic, D.D.; Vrecic, T.; Paunovic, K.; Salinger, S. Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy: A 24-Month Cohort Study. Medicina 2024, 60, 1760. https://doi.org/10.3390/medicina60111760
Dimitrijevic ZM, Mitic BP, Tasic DD, Vrecic T, Paunovic K, Salinger S. Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy: A 24-Month Cohort Study. Medicina. 2024; 60(11):1760. https://doi.org/10.3390/medicina60111760
Chicago/Turabian StyleDimitrijevic, Zorica M., Branka P. Mitic, Danijela D. Tasic, Tamara Vrecic, Karolina Paunovic, and Sonja Salinger. 2024. "Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy: A 24-Month Cohort Study" Medicina 60, no. 11: 1760. https://doi.org/10.3390/medicina60111760
APA StyleDimitrijevic, Z. M., Mitic, B. P., Tasic, D. D., Vrecic, T., Paunovic, K., & Salinger, S. (2024). Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy: A 24-Month Cohort Study. Medicina, 60(11), 1760. https://doi.org/10.3390/medicina60111760